Hanall Biopharma Co., Ltd. (009420.KS) KSC

Currency In KRW

AD

Valuation

Market Cap2.18T
Enterprise Value2.19T
P/E Ratio-95.63
PEG Ratio-0.15
Price/Sales Ratio14.41
Price/Book Ratio14.9
Enterprise/Revenue14.5
Enterprise/EBITDA-174.26

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-0.15
Operating Margin0.02
AD

Management Effectiveness

Return On Assets-0.1
Return On Equity-0.15

Income Statement

Revenue155.18B
Revenue/Share3,113.64
Gross Profit79.1B
EBITDA1.94B
Net Income-5.56B
Diluted EPS-111.55

Balance Sheet

Total Cash30.2B
Total Cash/Share578.01
Total Debt44.99B
Total Debt/Equity0.28
Current Ratio1.49
Book Value Per Share3,093.85

Price History

52-Week Change33.62
52-Week High73,000
52-Week Low32,600
Moving Average 50 Days52,233
Moving Average 200 Days52,082

Statistics

Average Volume330,601
Shares Outstanding50.86M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor10:1
Last Split DateMay 03, 2006
AD